1/15
09:19 am
nvcr
NovoCure (NASDAQ:NVCR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
Low
Report
NovoCure (NASDAQ:NVCR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
1/13
02:54 pm
nvcr
Why NovoCure Is Failing To Disrupt NSCLC [Seeking Alpha]
Low
Report
Why NovoCure Is Failing To Disrupt NSCLC [Seeking Alpha]
1/13
08:03 am
nvcr
NovoCure (NASDAQ:NVCR) had its price target lowered by analysts at HC Wainwright from $42.00 to $39.00. They now have a "buy" rating on the stock.
Low
Report
NovoCure (NASDAQ:NVCR) had its price target lowered by analysts at HC Wainwright from $42.00 to $39.00. They now have a "buy" rating on the stock.
1/12
07:00 am
nvcr
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
Low
Report
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
1/5
12:01 pm
nvcr
NovoCure (NASDAQ:NVCR) was given a new $20.00 price target on by analysts at Evercore ISI.
Low
Report
NovoCure (NASDAQ:NVCR) was given a new $20.00 price target on by analysts at Evercore ISI.
12/22
07:00 am
nvcr
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
12/1
07:44 am
nvcr
Novocure names Frank Leonard as CEO [Seeking Alpha]
Medium
Report
Novocure names Frank Leonard as CEO [Seeking Alpha]
12/1
07:00 am
nvcr
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
Medium
Report
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
11/26
07:00 am
nvcr
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
Low
Report
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
11/12
07:00 am
nvcr
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
Medium
Report
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
10/30
12:40 pm
nvcr
NovoCure (NASDAQ:NVCR) had its price target raised by analysts at HC Wainwright from $38.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
NovoCure (NASDAQ:NVCR) had its price target raised by analysts at HC Wainwright from $38.00 to $42.00. They now have a "buy" rating on the stock.
10/30
07:00 am
nvcr
Novocure Reports Third Quarter 2025 Financial Results
Medium
Report
Novocure Reports Third Quarter 2025 Financial Results
10/27
10:55 am
nvcr
NovoCure (NASDAQ:NVCR) had its price target lowered by analysts at JPMorgan Chase & Co. from $25.00 to $23.00. They now have a "neutral" rating on the stock.
Low
Report
NovoCure (NASDAQ:NVCR) had its price target lowered by analysts at JPMorgan Chase & Co. from $25.00 to $23.00. They now have a "neutral" rating on the stock.